Yamo Pharmaceuticals, based in New York, NY, is a cutting-edge pharmaceutical company specializing in the development of L1-79, a novel therapy designed to target the core symptoms of autism. With a focus on both the central nervous system and metabolic aspects of the disorder, Yamo's treatment has shown promising results in clinical trials, demonstrating good tolerability among patients.
Committed to advancing autism research, Yamo Pharmaceuticals is actively involved in future clinical studies and offers a compassionate use policy. With a dedicated team and a scientific advisory board, the company aims to provide effective solutions for patients and caregivers, addressing the challenges associated with autism.
Generated from the website